Initial Clinical Assessment for Suspected Autoimmune Disease
Suspected autoimmune disease should be approached as a syndrome with targeted testing guided by phenotype and organ involvement, rather than ordering broad panels without clinical direction.
A structured history, focused physical examination, and “organ-system first” laboratory and imaging selection is recommended for diagnostic efficiency.
History and Physical Examination Components
Key historical domains should include symptom pattern, inflammatory features, and organ-specific complaints.
Symptom and risk domains
- Pain and stiffness pattern should be characterized by duration and morning stiffness for possible inflammatory arthritis.
- Constitutional symptoms should be assessed for fever, weight loss, fatigue, and night sweats to evaluate inflammatory or systemic disease.
- Mucocutaneous symptoms should be assessed for photosensitive rash, oral or nasal ulcers, alopecia, Raynaud phenomenon, sicca symptoms, and rashes.
- Renal symptoms should be assessed for hematuria, foamy urine, edema, and hypertension.
- Pulmonary symptoms should be assessed for dyspnea, cough, pleuritic pain, and exertional limitation.
- Neurologic symptoms should be assessed for seizures, psychosis, focal deficits, headaches, and neuropathic symptoms.
- Vascular and thrombotic symptoms should be assessed for DVT/PE history, arterial thrombosis, pregnancy morbidity, and livedo reticularis.
Physical examination domains
- Joint examination should document synovitis distribution, tenderness, range of motion limitation, and deformities.
- Skin and mucosa examination should document rash morphology, ulcers, sclerodactyly, telangiectasias, and xerostomia signs.
- Salivary and ocular exam should assess lacrimal and salivary gland involvement for possible Sjögren syndrome.
- Pulmonary exam should assess for crackles and pleural findings for interstitial lung or serositis syndromes.
- Vascular exam should assess for abnormal perfusion patterns compatible with Raynaud phenomenon.
- Neurologic exam should assess focal deficits and cognitive changes when neuropsychiatric involvement is suspected.
Laboratory Testing Strategy
Laboratory workup should be selected to confirm immune activation, assess organ involvement, and support classification criteria for specific diseases.
Baseline “inflammation and organ involvement” testing
- CBC with differential should be obtained to evaluate cytopenias and leukopenia.
- CMP should be obtained to evaluate creatinine, liver enzymes, and electrolyte abnormalities.
- Urinalysis with microscopy should be obtained to evaluate proteinuria and hematuria.
- ESR and CRP should be obtained to support systemic inflammation.
Autoantibody and immune serology selection
- ANA should be used when connective tissue disease is in the differential because ANA is an entry criterion for SLE classification criteria. [1]
- Complement testing (C3 and C4) should be obtained when SLE is suspected because complement domains contribute to SLE classification weighting. [1]
- Antiphospholipid antibodies (lupus anticoagulant, anticardiolipin, and anti–β2-glycoprotein I) should be assessed when thrombosis, pregnancy morbidity, or suspected antiphospholipid-spectrum disease is present because antiphospholipid antibodies contribute to SLE classification weighting. [1]
- RF and ACPA should be obtained when inflammatory arthritis is present because RA classification criteria incorporate serology weighting for RF and ACPA positivity. [2]
- Sjögren-associated testing (anti-Ro/SSA, anti-La/SSB, objective ocular or salivary measures) should be obtained when sicca symptoms suggest primary Sjögren syndrome because the 2016 ACR/EULAR criteria include objective glandular and ocular features plus serology. [3]
- SSc testing should include evaluation for specific clinical pattern elements and autoantibodies because 2013 ACR/EULAR SSc classification criteria use an SSc-feature framework driven by skin thickening pattern and additional domains. [4]
Tissue or procedural testing
- Targeted biopsy or tissue confirmation should be pursued when noninvasive tests are insufficient and when histology is required for the suspected specific disease phenotype (for example, organ-threatening disease manifestations).
Imaging and Procedure Selection
Imaging should be directed by suspected organ involvement.
- Musculoskeletal imaging should be selected to document synovitis and erosive disease when inflammatory arthritis is suspected.
- Chest imaging (radiography or HRCT) should be obtained when dyspnea, cough, abnormal lung exam, or suspected interstitial lung disease is present.
- Vascular imaging should be obtained for suspected large-vessel vasculitis, arterial thrombosis, or unexplained ischemic syndromes based on clinical context.
- Salivary gland and ocular procedural tests should be obtained when sicca symptoms suggest Sjögren syndrome and objective criteria are required.
Monotherapy vs Combination Therapy Decision Impact From the Workup
Diagnostic testing should prioritize organ-threatening disease confirmation before immunotherapy intensity decisions.
- Uncomplicated symptom syndromes without objective inflammation or organ involvement should be evaluated for non-autoimmune mimics before escalation.
- High-risk phenotypes (renal involvement in suspected SLE, rapidly progressive neurologic disease, severe ILD, or vasculitic presentations) should trigger expedited confirmatory testing prior to immunosuppression initiation.
Differentiation Using Common Autoimmune Classification Criteria
Classification criteria are primarily intended for consistent case definition for clinical studies, but they also provide structured diagnostic anchors for common autoimmune diseases.
Systemic lupus erythematosus (SLE)
SLE classification criteria require ANA positivity as an entry criterion, then assign weighted criteria across clinical and immunologic domains with a total score threshold. [1]
Key SLE domain groupings include constitutional, hematologic, neuropsychiatric, mucocutaneous, serosal, musculoskeletal, renal, and immunologic domains (including antiphospholipid antibodies, complement proteins, and SLE-specific antibodies). [1]
Clinical differentiators from the workup
- Prominent cytopenias, renal findings on urinalysis, serositis, and multi-domain immune serology supports SLE structure consistent with the SLE criteria framework. [1]
Rheumatoid arthritis (RA)
RA classification criteria incorporate:
- Clinical synovitis distribution across joint categories. [2]
- Serology weighting for RF and ACPA positivity. [2]
- Acute-phase reactants weighting using ESR/CRP. [2]
Clinical differentiators from the workup
- Symmetric inflammatory small-joint synovitis plus RF/ACPA positivity with elevated ESR/CRP aligns with RA classification structure. [2]
Primary Sjögren syndrome
Primary Sjögren classification criteria evaluate:
- Labial salivary gland biopsy (focus score) and/or objective ocular and salivary tests. [3]
- Autoantibodies (notably anti-Ro/SSA and anti-La/SSB). [3]
Clinical differentiators from the workup
- Sicca symptoms with objective ocular findings and/or salivary gland objective tests plus SSA/SSB positivity supports the Sjögren classification pathway. [3]
Systemic sclerosis (SSc)
2013 ACR/EULAR SSc classification criteria emphasize a structured approach using SSc-relevant clinical features, with skin thickening patterns and additional domains that include autoantibody and other organ features. [4]
Clinical differentiators from the workup
- Raynaud phenomenon plus skin thickening pattern evaluation with supportive additional organ or serologic domains supports SSc classification structure. [4]
Common Pitfalls to Avoid
- Testing should not begin with broad multiplex autoantibody panels without clinical phenotype because entry criteria-based frameworks (notably ANA for SLE) create structured interpretation pathways. [1]
- RA serology and acute-phase reactants should not be interpreted without documented objective synovitis because RA classification criteria weight clinical joint involvement and serologic and inflammatory components together. [2]
- Sicca symptoms should not be treated as diagnostic without objective ocular or salivary measures or biopsy/serology alignment because primary Sjögren classification criteria incorporate objective findings and serology. [3]
- SSc should not be treated as present based solely on one symptom such as Raynaud phenomenon because 2013 SSc criteria structure includes skin thickening pattern and additional domains rather than Raynaud alone. [4]
Treatment Targeting Goals After Diagnostic Workup Confirmation
Diagnostic confirmation should enable:
- Organ-specific risk stratification (renal, neurologic, pulmonary, and vascular risk).
- Disease category-directed monitoring plans (autoantibody-driven and organ-specific surveillance).
- Selection of immunotherapy intensity consistent with disease phenotype rather than symptom-only syndromes.